福瑞医科
(300049)
| 流通市值：96.01亿 | | | 总市值：108.50亿 |
| 流通股本：2.34亿 | | | 总股本：2.64亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,141,439,239.95 | 754,789,476.99 | 360,140,767.62 | 1,595,388,937.81 |
| 营业收入 | 1,141,439,239.95 | 754,789,476.99 | 360,140,767.62 | 1,595,388,937.81 |
| 二、营业总成本 | 842,216,150.29 | 580,721,995.02 | 276,499,345 | 1,213,306,309.13 |
| 营业成本 | 277,744,165.43 | 182,930,439.85 | 90,421,329.81 | 399,359,578.05 |
| 税金及附加 | 12,392,140.39 | 9,794,749.85 | 2,866,288.41 | 10,992,163.08 |
| 销售费用 | 273,583,659.27 | 191,871,912.02 | 90,454,277.02 | 390,245,601.39 |
| 管理费用 | 205,359,682.54 | 148,584,077.92 | 72,251,303.87 | 284,948,972.96 |
| 研发费用 | 96,888,492.19 | 65,397,710.66 | 31,522,653.2 | 111,203,556.9 |
| 财务费用 | -23,751,989.53 | -17,856,895.28 | -11,016,507.31 | 16,556,436.75 |
| 其中:利息费用 | 3,321,265.69 | 2,192,329.71 | 910,858.33 | 3,224,057.79 |
| 其中:利息收入 | 16,805,988.55 | 10,711,329.54 | 4,617,831.15 | 19,289,158.65 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,163,758.69 | 2,163,758.69 | - | 25,291,768.37 |
| 加:投资收益 | -3,488,896.69 | -6,600,495.76 | -2,029,487.59 | -8,457,731.9 |
| 资产处置收益 | -35,975.49 | 100,893.89 | -89,371.61 | 378,455.47 |
| 资产减值损失(新) | 466,093.64 | -4,947.21 | - | -33,517,494.97 |
| 信用减值损失(新) | -432,336.16 | -3,447,893.86 | -3,756,834.27 | 1,755,702.22 |
| 其他收益 | 3,433,085.68 | 2,286,708.58 | 1,218,823.12 | 763,236.4 |
| 四、营业利润 | 301,328,819.33 | 168,565,506.3 | 78,984,552.27 | 368,296,564.27 |
| 加:营业外收入 | 76,721.26 | 14,591.83 | 480.62 | 843,121.66 |
| 减:营业外支出 | 11,395,126.69 | 9,131,523.87 | 5,904,360.79 | 18,578,209.69 |
| 五、利润总额 | 290,010,413.9 | 159,448,574.26 | 73,080,672.1 | 350,561,476.24 |
| 减:所得税费用 | 73,767,630.08 | 44,916,339.17 | 20,958,336.98 | 92,140,691.23 |
| 六、净利润 | 216,242,783.82 | 114,532,235.09 | 52,122,335.12 | 258,420,785.01 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 216,242,783.82 | 114,532,235.09 | 52,122,335.12 | 258,420,785.01 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 133,755,062.97 | 63,940,433.93 | 31,794,294.84 | 154,089,068.25 |
| 少数股东损益 | 82,487,720.85 | 50,591,801.16 | 20,328,040.28 | 104,331,716.76 |
| 扣除非经常损益后的净利润 | 130,001,271.49 | 64,781,585.88 | 33,401,661.37 | 134,599,041.9 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.51 | 0.24 | 0.12 | 0.58 |
| (二)稀释每股收益 | 0.51 | 0.24 | 0.12 | 0.58 |
| 八、其他综合收益 | -103,916,570.86 | -67,800,752.91 | -47,067,187.84 | 98,609,354.51 |
| 归属于母公司股东的其他综合收益 | -68,471,139.12 | -41,905,776.1 | -30,460,123.62 | 74,413,565.3 |
| 九、综合收益总额 | 112,326,212.96 | 46,731,482.18 | 5,055,147.28 | 357,030,139.52 |
| 归属于母公司股东的综合收益总额 | 65,283,923.85 | 22,034,657.83 | 1,334,171.22 | 228,502,633.55 |
| 归属于少数股东的综合收益总额 | 47,042,289.11 | 24,696,824.35 | 3,720,976.06 | 128,527,505.97 |
| 公告日期 | 2026-10-30 | 2026-08-25 | 2026-04-28 | 2026-03-25 |
| 审计意见(境内) | | | | 标准无保留意见 |